Professor Qing Zou: Advancing Comprehensive Therapy and “Full-Course Management” Systems for Urologic Malignancies
In recent years, the management of urologic malignancies—including kidney cancer and bladder cancer—has been moving toward a new era of comprehensive care, innovative treatments, multidisciplinary collaboration (MDT), and multi-technology integration. The goal is to build a “full-course management” system that maximizes clinical benefit for patients by combining advances from across specialties. At the 2025 Pujiang Uro-Oncology Conference, Professor Qing Zou of Jiangsu Cancer Hospital shared the latest developments in the diagnosis and treatment of representative urologic tumors such as kidney cancer and non–muscle-invasive bladder cancer (NMIBC). He also discussed the implementation of innovative technologies, MDT collaboration, and the experience of building a full-course management system.
